Polymorphisms of MUC16 (CA125) and MUC1 (CA15.3) in Relation to Ovarian Cancer Risk and Survival by Williams, Kristina A. et al.
 
Polymorphisms of MUC16 (CA125) and MUC1 (CA15.3) in Relation
to Ovarian Cancer Risk and Survival
 
 
(Article begins on next page)
The Harvard community has made this article openly available.
Please share how this access benefits you. Your story matters.
Citation Williams, Kristina A., Kathryn L. Terry, Shelley S. Tworoger,
Allison F. Vitonis, Linda J. Titus, and Daniel W. Cramer. 2014.
“Polymorphisms of MUC16 (CA125) and MUC1 (CA15.3) in
Relation to Ovarian Cancer Risk and Survival.” PLoS ONE 9 (2):
e88334. doi:10.1371/journal.pone.0088334.
http://dx.doi.org/10.1371/journal.pone.0088334.
Published Version doi:10.1371/journal.pone.0088334
Accessed February 19, 2015 3:21:41 PM EST
Citable Link http://nrs.harvard.edu/urn-3:HUL.InstRepos:11879765
Terms of Use This article was downloaded from Harvard University's DASH
repository, and is made available under the terms and conditions
applicable to Other Posted Material, as set forth at
http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-
use#LAAPolymorphisms of MUC16 (CA125) and MUC1 (CA15.3) in
Relation to Ovarian Cancer Risk and Survival
Kristina A. Williams
1,2, Kathryn L. Terry
1,2,3, Shelley S. Tworoger
3,4, Allison F. Vitonis
1, Linda J. Titus
5,
Daniel W. Cramer
1,2,3*
1Obstetrics and Gynecology Epidemiology Center, Department of Obstetrics and Gynecology, Brigham and Women’s Hospital, Boston, Massachusetts, United States of
America, 2Harvard Medical School, Boston, Massachusetts, United States of America, 3Department of Epidemiology, Harvard School of Public Health, Boston,
Massachusetts, United States of America, 4Channing Division of Network Medicine, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School,
Boston, Massachusetts, United States of America, 5Department of Community & Family Medicine, Department of Pediatrics, Dartmouth-Hitchcock Medical Center
Lebanon, New Hampshire, United States of America
Abstract
Objective: To examine single nucleotide polymorphism (SNPs) in MUC16 (CA125) and MUC1 (CA15.3) in relation to ovarian
cancer risk and survival.
Methods: We genotyped germline variants of MUC16 (rs2547065, rs1559168, rs12984471, rs2121133) and MUC1 (rs2070803,
rs4072037, rs1045253) using samples collected from 758 ovarian cancer cases and 788 controls enrolled in the New England
Case-Control Study between 2003 and 2008. We calculated age-adjusted odds ratios (OR) and 95% confidence intervals (CIs)
for disease risk using unconditional and polytomous logistic regression and hazard ratios (HR) for survival using Cox
proportional hazard ratios. In a subset of cases, we compared log-normalized CA125 values by genotype using generalized
linear models.
Results: Cases homozygous for the variant allele of MUC16 SNP, rs12984471, had poorer overall survival (log-rank p=0.03)
and higher CA125 levels, especially cases over age 65 (p=0.01). For MUC1 SNP, rs4072037, women homozygous for the G
variant had a non-significantly decreased risk for serous invasive types but elevated risk for serous borderline tumors,
mucinous borderline and invasive tumors, and endometrioid tumors. Women with the variant allele of MUC16 SNP,
rs2547065, especially those who were homozygous had an elevated risk for ovarian cancer; but this association was not
confirmed in an independent dataset.
Conclusion: This targeted screen of seven polymorphisms of MUC16 and MUC1 genes failed to identify and confirm effects
on ovarian cancer risk overall. However, there may be effects of MUC16 rs12984471 on survival and MUC1 rs4072037 on risk
for histologic types of ovarian cancer other than invasive serous. Further study is warranted.
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Introduction
The tethered human mucins (MUC) are a family of large,
heavily glycosylated transmembrane proteins that have a diverse
range of functions [1]. CA125, or MUC16, is the largest
glycoprotein of the mucin family, and is normally expressed in
the epithelial lining of various tissues, especially that of the female
reproductive tract [1]. CA125 is elevated in the serum of about
82% of ovarian cancer patients and is used to predict recurrence
[2,3]. CA15.3, or MUC1, also is expressed in the epithelial lining
of various tissues, exhibiting strong expression in the mammary
gland and the female reproductive tract during pregnancy and
lactation. CA15.3 is over-expressed in a wide variety of cancers,
including breast and ovarian [1,4]. Although these two mucins are
best known as tumor markers, evidence suggests that they may
play a role in cancer metastasis, tumor growth and survival,
inhibition of immune response, and prognosis [1,5,6].
Several studies have examined genetic variation in genes
involved in glycosylation of CA125 and CA15.3 and ovarian
cancer risk, observing overall null associations [7,8,9,10]; however,
there are few studies of genetic variation specifically in MUC16 or
MUC1 and their association with ovarian cancer risk or survival.
Therefore, we examined the association between a targeted set of
single nucleotide polymorphisms (SNPs) in MUC16 (rs2547065,
rs1559168, rs12914471, rs2121133) and MUC1 (rs2070803,
rs4072037, rs1045253) in relation to ovarian cancer risk and
survival.
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Ethics Statement
Institutional Review Boards at Brigham and Women’s Hospital,
Dana Farber Cancer Institute, and Dartmouth Medical School
approved the studies and all study participants signed informed
consent.
Study Population and Design
Data and specimens come from the last enrollment phase of the
New England Case Control Study of ovarian cancer from 2003–
2008 (NECC). Details regarding case and control enrollment for
this study are described elsewhere [11,12]. Briefly, of 1610
incident cases of ovarian cancer identified through hospital tumor
boards and statewide cancer registries between 2003 and 2008,
897 of 1238 eligible agreed to participate. Controls were identified
through town books in eastern Massachusetts and drivers’ license
lists in New Hampshire. Exclusion criteria for controls included
inability to be contacted, history of bilateral oophorectomy,
language barriers, or relocation outside of the study area. Of 2522
controls identified, 1673 were eligible and 857 agreed to
participate.
After written informed consent, demographic information,
reproductive and medical history, and lifestyle factors were
assessed by in-person interviews and heparinized blood samples
were collected.
Genotyping
DNA was extracted and genotyping was performed at the
Dana-Farber/Harvard Cancer Center (DF/HCC) High Through-
put Polymorphism Core, an affiliate of the Partners Healthcare
Center for Personalized Genetic Medicine. DNA was extracted
from buffy coat samples using QIAmp (Qiagen, Chatworth, CA).
Genotyping of MUC16 (rs2547065, rs1559168, rs12914471,
rs2121133) and MUC1 (rs2070803, rs4072037, rs1045253) was
performed using 59 nuclease assays (TaqmanH) on the Applied
Biosystems Prism 7900HT Sequence Detection System (Applied
Biosystems, Foster City, California). Primers, probes, and condi-
tions for genotyping assays are available upon request. Replicates
of 10% of the samples were included for quality control.
Laboratory personnel were blinded to case control status and
the location of quality controls.
Based on preliminary data, we sought to validate one of the
SNPs in an independent dataset. We used samples from 534 cases
and 1513 controls from the Nurses’ Health Study cohorts (NHS/
NHSII) [13]. The NHS includes 121,700 participants, 32,826 of
whom provided blood samples in 1990 and 33,040 who gave
buccal cells specimens from 2001–2004. The NHSII includes
116,430 participants, of whom 29,611 provided blood from 1996–
1999 and 29,859 provided buccal cells from 2004–2006. Cases
were identified after sample collection and before June 1, 2010
(NHS) or June 1, 2009 (NHSII). Demographic information on
NHS and NHSII participants have been described previously [13].
Briefly, participants in both cohorts are predominantly white (.
96%), but NHS is an older cohort than NHSII which is reflected
in participants’ mean age (NHS:65years, NHSII:49years), ever a
child birth (95% NHS, 76% NHSII), and ever oral contraceptive
use (45% NHS, 81% NHSII).
Preoperative CA125 Levels
We reviewed all medical records and computerized laboratory
reports for cases who received care at Brigham and Women’s
Hospital or Massachusetts General Hospital (n=809) [14]. CA125
values were abstracted for women whose levels had been measured
prior to surgery and/or neoadjuvant chemotherapy. We were able
to retrieve CA125 values on 353 of the cases genotyped in this
study. Data on CA15.3 were not available.
Statistical Analysis
We used chi-square tests to assess Hardy–Weinberg Equilibrium
(HWE) for each SNP among controls. Unconditional logistic
regression was used to calculate overall odds ratios (OR) and 95%
confidence intervals (95% CI) of ovarian cancer risk adjusted for
age (continuous), study center (Massachusetts or New Hampshire),
and race (white or non-white). The more common allele for each
SNP served as the reference group in the regression models. Co-
dominant (heterozygous vs. wild type or homozygous variant vs.
wild type), recessive (homozygous variant vs. heterozygous and
wild type), and per allele (trend test) models were computed.
Multivariate regression models were additionally adjusted for
family history of ovarian or early onset breast cancer and a
personal history of breast cancer.
Polytomous logistic regression was used to calculate OR
(95%CI) for risk of various histological subtypes adjusted for age,
study center, and race. Likelihood ratio tests were used to test for
heterogeneity across histologic categories (serous borderline, serous
invasive [includes high grade transitional cell and mixed serous],
mucinous [borderline and invasive], endometrioid or mixed
endometrioid/clear cell, clear cell, undifferentiated [includes
unspecified and Brenner tumours]) comparing a model that allows
the estimate of the association to vary by histologic type to a model
that restricts to one estimate of the association for all histologic
types.
Cox proportional hazard models (HR) were used to examine the
association between each polymorphism and survival, adjusting for
study center and race and in a secondary model for stage (I-IV)
and histology (serous, non-serous). Co-dominant, recessive, and
per allele models were used as described in supplemental methods
(Methods S1). The Kaplan–Meier method was used to estimate
survival curves and calculate log-rank statistics.
Geometric mean CA125 values by genotype were calculated for
each MUC16 polymorphism. Statistical analyses used general
linear regression, adjusted for age, race, and time between CA125
measurement and diagnosis (#30 days, .30days, missing), using
continuous log transformed CA125 levels and a variable that
represents increasing variant alleles for each polymorphism (0, 1,
2). CA125 levels can vary during the menstrual cycle, and levels
vary between pre and postmenopausal women [15,16], so we
stratified these analyses into three age/menopausal categories
(premenopausal, ‘‘midlife’’ postmenopausal (age,65), and ‘‘elder-
ly’’ postmenopausal (age.=65)). All analyses were performed
using SAS v 9.1 (SAS, Cary, North Carolina) and Intercooled
Stata 9 (StataCorp LP, College Station, Texas).
Results
A total of 758 women with ovarian cancer and 788 controls
were included in the final analytic sample (Table 1). For both cases
and controls, mean age was 54. Our study population consisted
primarily of Caucasian women (.95%) and white ethnicity was
more common among controls. On average, controls had higher
parity, longer duration of oral contraceptive use, and a higher
frequency of tubal ligation, endometriosis or painful periods, and a
personal history of breast cancer. Family history of ovarian or
early onset breast cancer, smoking status, and menopausal status
did not differ significantly between cases and controls. Serous
invasive (49.7%) was the most frequent histologic subtype among
cases followed by endometrioid (17.8%).
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and had genotyping success greater than 95% except for
rs2547065 (93%). In general the minor allele frequencies (MAF)
we found for our controls were comparable to that of the
Caucasian European (CEU) HapMap populations (data not
shown). In the NECC study, one of the four MUC16 polymor-
phisms was associated with ovarian cancer risk (Table 2). For
polymorphism rs2547065, we observed an increase in ovarian
cancer risk (per allele OR=1.26, 95% CI: 1.09–1.47). Risk was
most apparent for the homozygous variant genotype when
compared to the wild type genotype (OR=1.68, 95% CI: 1.23–
2.29). However, polymorphism rs2547065 was not associated with
ovarian cancer risk (per allele: OR=1.05, 95% CI: 0.91–1.21) in
an independent dataset including 534 cases and 1513 controls
from the Nurses’ Health Study cohorts (NHS/NHSII). There was
no significant heterogeneity by histologic type for any of the
MUC16 polymorphisms.
For MUC1, none of the polymorphisms we tested were
significantly associated with overall ovarian cancer risk in the
per allele model. Women carrying two copies of the MUC1
polymorphism rs2070803 variant had an increased risk of serous
invasive cancer of borderline statistical significance (OR=1.35,
95% CI 0.99–1.86) in the recessive model. Although we observed
no significant risk associated with MUC1 polymorphism rs4072037
overall, significant heterogeneity by histology was observed when
evaluating the recessive model for this polymorphism (p-hetero-
geneity=0.02). Women homozygous for the G variant of
rs4072023 had a non-significantly decreased risk for invasive
serous cancers but elevated risks for serous borderline tumors
(OR=1.91, 95% CI 1.08–3.36), mucinous borderline and invasive
(OR=1.68, 95% CI 1.00–2.83), and endometrioid tumors
(OR=1.54, 95% CI 1.01–2.33). Adjusting for family history of
ovarian or early onset breast cancer and personal history of breast
cancer did not change estimates for any of the MUC1 or MUC16
polymorphisms.
In examining the effect of mucin polymorphisms and survival,
we observed poorer overall survival among women carrying the
variant allele of MUC16 polymorphism rs12984471 (log-rank
p=0.03; Figure 1A) as well as an increased mortality (age-adjusted
HR=1.23 95% CI: 1.02–1.48, Table 3). These associations were
strongest in women age 65 and older (log-rank p=0.02; age-
adjusted HR=1.53 95% CI: 1.07–2.19) (Figure 1B). Mortality was
57% greater for women who were homozygous for the variant
allele of rs12984471 (age-adjusted HR=1.57 95% CI: 1.09–2.28).
Adjustment for stage and histology attenuated the association
(multivariate HR=1.32 95% CI: 0.91–1.92); stage was the
strongest predictor of survival. No other associations between the
remaining mucin polymorphisms and survival were observed.
Finally, we evaluated the association between MUC16 poly-
morphisms and serum levels of CA125 measured preoperatively
(Table 4). Among all cases, we observed no linear associations
between MUC16 polymorphisms and CA125 levels; however,
rs2121133 had the highest CA125 levels for heterozygotes (319.9)
and lowest for homozygous variants (110.0) (p=0.03). Among
elderly postmenopausal women, increasing variant alleles of
polymorphism rs12984471 were significantly associated with
increasing levels of CA125 (p=0.02).
Discussion
The MUC1 gene is located on 1q21–22, which is a region
frequently altered in both neoplastic and non-neoplastic disorders.
MUC1 gene amplification due to increased gene copy number has
been observed in ovarian, breast, papillary thyroid, and gastric
cancers [17,18,19,20]. Neoplastic mammary cells have been
shown to have a high frequency of altered DNA within the
variable nucleotide repeat region (VNTR) of MUC1- the largest
region of the this protein and the site of O-glycosylation [1,21,22].
MUC1 has been shown to be essential for ovarian cancer
tumorigenesis in mouse models and is over expressed in
approximately 90–100% of serous carcinomas [23,24,25]. The
three MUC1 SNPs we studied were selected based on previous
publications that studied associations between MUC1 polymor-
phisms and gastrointestinal cancers [26,27]. Polymorphism
rs4072037 has been correlated with serum MUC1 levels and is
known to play a role in alternative splicing [28,29]. Polymorphism
rs2070803 is located upstream of the MUC1 gene in a large LD
block, and polymorphism rs1045253 was previously identified as a
tagSNP representative of the MUC1 region [30,31,32]. None of
these three polymorphisms affected risk or survival for ovarian
cancer overall. Women who were homozygous for the variant G
allele of rs2070803 had a 35% elevation in risk for invasive serous
ovarian cancer. Although our finding was of borderline statistical
Table 1. Descriptive characteristics of ovarian cancer cases
and controls, New England-based ovarian cancer case-control
study 2003–2008.
Controls Cases
Variable N=788 N=758 p
b
Age, mean (SD) 54.4 (11.8) 54.2 (11.3) 0.77
Study Center
Massachusetts 670 (85.0) 609 (80.3) 0.01
New Hampshire 118 (15.0) 149 (19.7)
White Ethnicity, n (%) 774 (98.2) 715 (94.3) ,0.0001
Parous, n (%) 652 (82.7) 522 (68.9) ,0.0001
Mean Pregnancies
Among Parous (SD)
2.6 (1.2) 2.4 (1.2) 0.01
Oral Contraceptive Use, n (%) 541 (68.7) 439 (57.9) ,0.0001
Mean Years Among Users (SD) 6.3 (5.3) 5.1 (5.0) 0.0003
Tubal Ligation, n (%) 176 (22.3) 92 (12.1) ,0.0001
Ever Smoker, n (%) 405 (51.4) 398 (52.5) 0.66
Menopausal Status, n (%)
Premenopausal 294 (37.3) 278 (36.7) 0.90
Postmenopausal, Age ,65 346 (43.9) 333 (43.7)
Postmenopausal, Age $65 148 (18.8) 149 (19.7)
Endometrioses/Painful Periods,
n( % )
279 (35.5) 347 (45.8) ,0.0001
Family History,
a n (%) 62 (7.9) 74 (9.8) 0.19
Personal History of Breast
Cancer, n (%)
35 (4.4) 67 (8.8) 0.0005
Histologic Subtype, n (%)
Serous Borderline 62 (8.2)
Serous Invasive 385 (50.8)
Mucinous 75 (9.9)
Endometrioid 134 (17.7)
Clear Cell 50 (6.6)
Other/Undifferentiated 52 (6.9)
Cases and controls are frequency matched by age.
aIncludes ovarian and early onset (before age 50) breast cancers.
bp value from chi square or t-test.
doi:10.1371/journal.pone.0088334.t001
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case-control study, 2003–2008.
Controls (N=788) All Cases (N=758) Serous Invasive Cases (N=385)
MAF N(%) N(%) OR(95% CI)
a N (%) OR (95% CI)
b phet
c
MUC16
RS12984471 33%
GG 348 (45.2) 326 (44.7) 1.00 (ref) 158 (43.3) 1.00 (ref) 0.74
d
CG 338 (43.9) 307 (42.1) 1.01 (0.81, 1.25) 157 (43.0) 1.05 (0.80, 1.37)
CC 84 (10.9) 97 (13.3) 1.28 (0.92, 1.79) 50 (13.7) 1.36 (0.91, 2.02)
Per C Allele 1.09 (0.94, 1.27) 1.13 (0.94, 1.36) 0.64
e
CC vs. GG/GC 1.28 (0.93, 1.75) 1.32 (0.91, 1.93) 0.35
f
RS1559168 18%
TT 660 (85.6) 630 (86.3) 1.00 (ref) 322 (87.7) 1.00 (ref)
AT 107 (13.9) 96 (13.2) 0.92 (0.68, 1.24) 43 (11.7) –
AA 4 (0.5) 4 (0.5) 1.06 (0.26, 4.26) 2 (0.5) –
Per A Allele 0.94 (0.71, 1.24) 0.84 (0.60, 1.21) 0.36
e
AA vs. TT/AT 1.07 (0.26, 4.31) –
RS2121133 33%
AA 377 (50.2) 393 (55.0) 1.00 (ref) 193 (53.3) 1.00 (ref) 0.65
d
AG 318 (42.3) 277 (38.7) 0.84 (0.68, 1.05) 149 (41.2) 0.92 (0.71, 1.20)
GG 56 (7.5) 45 (6.3) 0.78 (0.51, 1.18) 20 (5.5) 0.69 (0.40, 1.18)
Per G Allele 0.86 (0.73, 1.02) 0.88 (0.72, 1.08) 0.48
e
GG vs. AA/AG 0.84 (0.55, 1.26) 0.71 (0.42, 1.21) 0.69
f
RS2547065 39%
GG 269 (36.7) 223 (31.9) 1.00 (ref) 113 (32.4) 1.00 (ref) 0.96
d
GC 359 (49.0) 330 (47.2) 1.11 (0.88, 1.40) 165 (47.3) 1.09 (0.82, 1.46)
CC 104 (14.2) 146 (20.9) 1.68 (1.23, 2.29) 71 (20.3) 1.61 (1.11, 2.34)
Per C Allele 1.26 (1.09, 1.47) 1.24 (1.03, 1.48) 0.90
e
CC vs. GG/GC 1.58 (1.20, 2.09) 1.53 (1.09, 2.13) 0.86
f
MUC1
RS1045253 30%
GG 355 (47.7) 322 (44.5) 1.00 (ref) 148 (40.9) 1.00 (ref) 0.63
d
GA 332 (44.4) 338 (46.7) 1.09 (0.88, 1.35) 180 (49.7) 1.25 (0.96, 1.63)
AA 58 (7.8) 63 (8.7) 1.13 (0.76, 1.67) 34 (9.4) 1.41 (0.89, 2.24)
Per A Allele 1.07 (0.91, 1.26) 1.21 (1.00, 1.48) 0.33
e
AA vs. GG/GA 1.08 (0.74, 1.58) 1.26 (0.82, 1.95) 0.51
f
RS2070803 48%
AA 253 (33.1) 228 (31.3) 1.00 (ref) 96 (26.6) 1.00 (ref) 0.30
d
AG 386 (50.5) 346 (47.5) 0.96 (0.76, 1.21) 186 (51.5) 1.22 (0.91, 1.64)
GG 125 (16.4) 155 (21.3) 1.27 (0.94, 1.71) 79 (21.9) 1.43 (1.07, 2.22)
Per G Allele 1.10 (0.95, 1.28) 1.23 (1.03, 1.47) 0.46
e
GG vs. AA/AG 1.30 (0.99, 1.69) 1.35 (0.99, 1.86) 0.84
f
RS4072037 47%
AA 214 (28.3) 226 (31.1) 1.00 (ref) 118 (32.9) 1.00 (ref) 0.06
d
AG 376 (49.7) 329 (45.3) 0.87 (0.69, 1.11) 174 (48.5) 0.87 (0.65, 1.16)
GG 167 (22.1) 172 (23.7) 1.06 (0.80, 1.41) 67 (18.7) 0.78 (0.54, 1.11)
Per G Allele 1.02 (0.88, 1.18) 0.89 (0.74, 1.06) 0.12
e
GG vs. AA/AG 1.15 (0.90, 1.47) 0.85 (0.62, 1.16) 0.02
f
aOR (95%CI) modeled with unconditional logistic regression; adjusted for age, study center, and race (white, non-white).
bOR (95%CI) modeled with polytomous logistic regression adjusted for age, study center, and race.
cp-values for heterogeneity (het) are computed with likelihood ratio tests comparing a model that allows the estimate of the association to vary by histologic type
(serous borderline, serous invasive, mucinous, endometrioid, clear cell, undifferentiated) to a model that restricts to one estimate of the association for all histologic
MUC16 and MUC1 SNPs and Ovarian Cancer Risk
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dphet for co-dominant model.
ephet for per allele model.
fphet for recessive model.
doi:10.1371/journal.pone.0088334.t002
Figure 1. Kaplan–Meier estimates of survival according to rs12984471 genotype among women with epithelial ovarian cancer,
New-England based case control study, 2003–2008. A. All women B. Postmenopausal women age 65 and older.
doi:10.1371/journal.pone.0088334.g001
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case-control study, 2003–2008.
Age-Adjusted Multivariate Age-Adjusted Multivariate
HR (95% CI)
a HR (95% CI)
b HR (95% CI)
a HR (95% CI)
b
MUC16
RS12984471
GG 1.00 (ref) 1.00 (ref) 1.00 (ref) 1.00 (ref)
CG 1.13 (0.85, 1.50) 1.13 (0.85, 1.51) 1.16 (0.85, 1.58) 1.15 (0.85, 1.57)
CC 1.57 (1.09, 2.28) 1.32 (0.91, 1.92) 1.17 (0.75, 1.81) 1.11 (0.72, 1.73)
Per C Allele 1.23 (1.02, 1.48) 1.15 (0.96, 1.37) 1.10 (0.90, 1.35) 1.08 (0.88, 1.32)
CC vs. GG/GC 1.48 (1.06, 2.07) 1.25 (0.89, 1.75) 1.08 (0.72, 1.63) 1.04 (0.69, 1.56)
RS1559168
TT 1.00 (ref) 1.00 (ref) 1.00 (ref) 1.00 (ref)
AT 1.00 (0.68, 1.47) 1.13 (0.77, 1.67) 1.15 (0.75, 1.76) 1.16 (0.76, 1.77)
AA – – – –
Per A Allele 0.89 (0.61, 1.28) 1.02 (0.70, 1.47) 1.00 (0.67, 1.48) 1.04 (0.69, 1.54)
AA vs. TT/AT – – – –
RS2121133
AA 1.00 (ref) 1.00 (ref) 1.00 (ref) 1.00 (ref)
AG 0.86 (0.65, 1.12) 0.86 (0.65, 1.13) 0.92 (0.68, 1.24) 0.91 (0.68, 1.23)
GG 0.94 (0.54, 1.64) 0.95 (0.55, 1.65) 1.21 (0.66, 2.21) 1.11 (0.61, 2.02)
Per G Allele 0.91 (0.73, 1.13) 0.91 (0.73, 1.13) 1.00 (0.78, 1.27) 0.98 (0.77, 1.24)
GG vs. AA/AG 1.01 (0.59, 1.73) 1.01 (0.59, 1.74) 1.26 (0.70, 2.26) 1.16 (0.64, 2.08)
RS2547065
GG 1.00 (ref) 1.00 (ref) 1.00 (ref) 1.00 (ref)
GC 1.02 (0.76, 1.39) 0.97 (0.71, 1.31) 1.03 (0.74, 1.43) 0.99 (0.71, 1.38)
CC 1.04 (0.71, 1.51) 0.93 (0.64, 1.36) 0.76 (0.49, 1.18) 0.74 (0.47, 1.15)
Per C Allele 1.02 (0.85, 1.23) 0.97 (0.80, 1.16) 0.90 (0.73, 1.10) 0.88 (0.71, 1.08)
CC vs. GG/GC 1.02 (0.74, 1.42) 0.95 (0.69, 1.32) 0.75 (0.50, 1.11) 0.74 (0.50, 1.10)
MUC1
RS1045253
GG 1.00 (ref) 1.00 (ref) 1.00 (ref) 1.00 (ref)
GA 1.25 (0.94, 1.65) 1.12 (0.85, 1.47) 1.03 (0.75, 1.41) 1.05 (0.77, 1.42)
AA 0.99 (0.60, 1.65) 0.89 (0.54, 1.47) 0.78 (0.45, 1.35) 0.81 (0.48, 1.37)
Per A Allele 1.07 (0.88, 1.30) 1.01 (0.82, 1.24) 0.95 (0.76, 1.19) 0.95 (0.76, 1.19)
AA vs. GG/GA 0.89 (0.55, 1.44) 0.84 (0.53, 1.35) 0.77 (0.46, 1.29) 0.79 (0.48, 1.30)
RS2070803
AA 1.00 (ref) 1.00 (ref) 1.00 (ref) 1.00 (ref)
AG 0.90 (0.67, 1.21) 0.83 (0.62, 1.12) 0.80 (0.58, 1.12) 0.87 (0.63, 1.22)
GG 1.06 (0.74, 1.52) 1.02 (0.71, 1.47) 1.02 (0.69, 1.52) 1.05 (0.70, 1.57)
Per G Allele 1.01 (0.84, 1.22) 0.99 (0.82, 1.20) 0.99 (0.81, 1.23) 1.01 (0.82, 1.25)
GG vs. AA/AG 1.12 (0.82, 1.54) 1.15 (0.84, 1.57) 1.18 (0.84, 1.66) 1.15 (0.81, 1.61)
RS4072037
AA 1.00 (ref) 1.00 (ref) 1.00 (ref) 1.00 (ref)
AG 1.03 (0.76, 1.38) 1.02 (0.76, 1.38) 1.10 (0.80, 1.52) 1.16 (0.85, 1.60)
GG 0.84 (0.58, 1.21) 0.89 (0.61, 1.28) 0.85 (0.56, 1.30) 0.82 (0.53, 1.25)
Per G Allele 0.93 (0.78, 1.11) 0.95 (0.79, 1.14) 0.95 (0.78, 1.16) 0.94 (0.77, 1.14)
GG vs. AA/AG 0.83 (0.60, 1.14) 0.87 (0.64, 1.20) 0.80 (0.55, 1.17) 0.74 (0.51, 1.09)
Modeled with Cox proportional hazard ratios; ‘‘–’’ frequencies for this SNP were too low to compute co-dominant/recessive models.
aAdjusted for age, study center, and race.
bAdjusted for age, study center, race, stage (I-IV) and histologic subtype (non-serous, serous).
doi:10.1371/journal.pone.0088334.t003
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PLOS ONE | www.plosone.org 6 February 2014 | Volume 9 | Issue 2 | e88334significance, a Japanese study found risk for ‘‘diffuse’’ type gastric
cancer to be increased with possession of the G allele [31]. In tests
we did for heterogeneity by histologic type of ovarian cancer, only
rs4072037 varied with increased risks for types other than invasive
serous including especially serous borderline, mucinous, and
endometrioid. In general, all histologic types of epithelial ovarian
tumors, both benign and malignant, express MUC1 on the cell
surface by immunohistochemistry [33]. However a recent study
using gene expression proposed that MUC1 expression is low in
one subtype of invasive serous tumors [34].
The MUC16 gene is located at 19p13, which is altered in a
variety of cancers, especially ovarian. In ovarian carcinoma, 19p13
has been identified as the chromosome band most frequently
involved in structural rearrangement [35,36]. This region has also
been shown to be highly amplified in high grade serous carcinoma
[37]. Polymorphisms rs12984471, rs1559168, rs2121133 are
tagSNPs and were selected for our study because they are
representative of various regions of the MUC16 gene. The minor
alleles of rs12984471 and rs1559168 introduce missense mutations
while rs2121133 is within an intron [38]. Polymorphism
rs2547065 was selected because it was previously studied in
relation to epithelial ovarian cancer [39] and introduces a missense
mutation that could potentially contribute to a functional
modification of the gene product. Among the MUC16 polymor-
phisms studied, we observed associations between rs2547065 and
ovarian cancer risk and between rs12984471 and survival.
In a small study that examined two MUC16 variants including
rs2547065, Bouanene et al. observed that the CC genotype was
more frequent in cases (49%) than in controls (34%), similar in
direction to what we observed but not significant in their study
which included only 41 cases and 76 controls [39]. Despite the fact
that homozygous variant genotype (CC) of polymorphism
rs2547065 was associated with ovarian cancer risk overall and
invasive serous ovarian cancer in the NECC data, we were unable
to validate this finding in independent data from the Nurses’
Health Study. With positive results from our study, supportive
results from the only published study related to this SNP, but null
results from the NHS, validation will be necessary and is planned
within the Ovarian Cancer Association Consortium.
MUC16 polymorphism rs12984471 was the only SNP associ-
ated with survival. The variant allele, which conferred poorer
survival among all cases, also was correlated with high CA125
serum levels in postmenopausal women, especially those over the
age of 65. The possibility that the association between rs12984471
and survival may have a biologic basis is suggested by possible
functional consequences on MUC16 protein. Polymorphism
rs12984471 is located in the largely uncharacterized extracellular
subunit where the C variant is responsible for a conservative
missense mutation changing a glutamate to an aspartate [38,40].
Conservative amino acid changes are theorized to confer 40%
likelihood of gene function modification compared to a silent
mutation [41]. Thus, it is plausible that the missense mutations
caused by this polymorphism could influence the function of the
MUC16 gene product as suggested by its effects on CA125 levels in
cases.
In conclusion, our study examined four SNPs in MUC16
(CA125) and three SNPs in MUC1 (CA15.3) in relation to ovarian
cancer risk and survival in the New England Case-Control study.
Table 4. Geometric mean levels of preoperative serum CA125 levels among women with ovarian cancer by MUC16 gene
polymorphisms, New England-based ovarian case-control study, 2003–2008.
All Women Premenopausal Postmenopausal ,65 Postmenopausal $65
NG M p
a NG M p
a NG M p
a NG M p
a
RS12984471
GG 145 193.5 0.15 58 139.9 0.94 63 265.8 0.64 24 184.0 0.02
CG 145 254.6 41 166.2 65 290.7 39 319.9
CC 49 398.4 14 163.2 22 423.6 13 939.4
RS1559168
TT 303 242.1 0.68 98 161.9 0.98 133 277.5 0.40 72 325.5 0.89
AT 34 302.4 12 124.5 15 527.2 7 420.8
AA 1 102.9 0 – 1 102.9 0 –
RS2121133
AA 201 226.7 0.03 62 141.9 0.06 89 288.4 0.90 50 263.8 0.07
AG 121 319.9 45 224.5 52 313.4 24 650.1
GG 17 110.0 5 25.7 7 245.5 5 153.1
RS2547065
GG 98 194.2 0.16 39 192.5 0.10 41 166.5 0.06 18 281.6 0.74
GC 166 290.3 50 147.5 71 393.5 45 381.2
CC 67 186.9 20 88.9 32 232.6 15 315.4
Abbreviations: GM=Geometric mean.
amodeled with general linear regression; adjusted for age, study center, race and time between CA125 to diagnosis (#30days, .30days, missing).
doi:10.1371/journal.pone.0088334.t004
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PLOS ONE | www.plosone.org 7 February 2014 | Volume 9 | Issue 2 | e88334One of four MUC16 SNPs, rs2547065, was associated with
increased risk for ovarian cancer. A different MUC16 SNP,
rs12984471, was associated with survival and also correlated with
serum levels of CA125. Of the three MUC1 SNPs studied, we
found one, rs4072037, which displayed significant heterogeneity
by histologic type. We had the opportunity to examine one of
these findings, rs2547065 with increased risk, in data from the
Nurse’s Health Study. The finding was not validated raising the
issue of chance in explaining our findings. However, the
association of rs12984471 in MUC16 with survival has some
biologic support in that it is also correlated with CA125 levels.
Since our study population is composed of primarily Caucasian
women, we were not able to generalize our results to other
ethnicities. Our study should not be considered definitive because
we targeted SNPs as opposed to conducting a comprehensive gene
or genome wide investigation. Evaluation of a broader set of
tagging SNPs is planned in the Ovarian Cancer Association
Consortium.
Supporting Information
Methods S1 Supplementary methods on age and histologic type
classification, statistical models, and SNP selection and genotyp-
ing.
(DOCX)
Acknowledgments
We would like to thank the participants and staff of the NHS and NHSII
cohorts for their valuable contributions as well as the following state cancer
registries for their help: AL, AZ, AR, CA, CO, CT, DE, FL, GA, ID, IL,
IN, IA, KY, LA, ME, MD, MA, MI, NE, NH, NJ, NY, NC, ND, OH,
OK, OR, PA, RI, SC, TN, TX, VA, WA, WY. In addition, this study was
approved by the Connecticut Department of Public Health (DPH) Human
Investigations Committee. Certain data used in this publication were
obtained from the DPH. The authors assume full responsibility for analyses
and interpretation of these data.
Author Contributions
Conceived and designed the experiments: DWC KLT. Analyzed the data:
KAW AFV KLT. Wrote the paper: KAW KLT SST AFV LJT DWC.
References
1. Hattrup CL, Gendler SJ (2008) Structure and function of the cell surface
(tethered) mucins. Annu Rev Physiol 70: 431–457.
2. Bast RC, Jr., Klug TL, St John E, Jenison E, Niloff JM, et al. (1983)
A radioimmunoassay using a monoclonal antibody to monitor the course of
epithelial ovarian cancer. N Engl J Med 309: 883–887.
3. Buller RE, Berman ML, Bloss JD, Manetta A, DiSaia PJ (1992) Serum CA125
regression in epithelial ovarian cancer: correlation with reassessment findings
and survival. Gynecol Oncol 47: 87–92.
4. Giuntoli RL, 2nd, Rodriguez GC, Whitaker RS, Dodge R, Voynow JA (1998)
Mucin gene expression in ovarian cancers. Cancer Res 58: 5546–5550.
5. Wang L, Ma J, Liu F, Yu Q, Chu G, et al. (2007) Expression of MUC1 in
primary and metastatic human epithelial ovarian cancer and its therapeutic
significance. Gynecol Oncol 105: 695–702.
6. Theriault C, Pinard M, Comamala M, Migneault M, Beaudin J, et al. (2011)
MUC16 (CA125) regulates epithelial ovarian cancer cell growth, tumorigenesis
and metastasis. Gynecol Oncol 121: 434–443.
7. Sellers TA, Huang Y, Cunningham J, Goode EL, Sutphen R, et al. (2008)
Association of single nucleotide polymorphisms in glycosylation genes with risk
of epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev 17: 397–404.
8. Phelan CM, Tsai YY, Goode EL, Vierkant RA, Fridley BL, et al. (2010)
Polymorphism in the GALNT1 gene and epithelial ovarian cancer in non-
Hispanic white women: the Ovarian Cancer Association Consortium. Cancer
Epidemiol Biomarkers Prev 19: 600–604.
9. Goode EL, Maurer MJ, Sellers TA, Phelan CM, Kalli KR, et al. (2010)
Inherited determinants of ovarian cancer survival. Clin Cancer Res 16: 995–
1007.
10. Terry KL, Vitonis AF, Hernandez D, Lurie G, Song H, et al. (2010)
A polymorphism in the GALNT2 gene and ovarian cancer risk in four
population based case-control studies. Int J Mol Epidemiol Genet 1: 272–277.
11. Harris HR, Cramer DW, Vitonis AF, DePari M, Terry KL (2012) Folate,
vitamin B(6), vitamin B(12), methionine and alcohol intake in relation to ovarian
cancer risk. Int J Cancer 131: E518–529.
12. Vitonis AF, Titus-Ernstoff L, Cramer DW (2011) Assessing ovarian cancer risk
when considering elective oophorectomy at the time of hysterectomy. Obstet
Gynecol 117: 1042–1050.
13. Tworoger SS, Gates MA, Lee IM, Buring JE, Titus-Ernstoff L, et al. (2009)
Polymorphisms in the vitamin D receptor and risk of ovarian cancer in four
studies. Cancer Res 69: 1885–1891.
14. Cramer DW, Vitonis AF, Welch WR, Terry KL, Goodman A, et al. (2010)
Correlates of the preoperative level of CA125 at presentation of ovarian cancer.
Gynecol Oncol 119: 462–468.
15. Skates SJ, Mai P, Horick NK, Piedmonte M, Drescher CW, et al. (2011) Large
prospective study of ovarian cancer screening in high-risk women: CA125 cut-
point defined by menopausal status. Cancer Prev Res (Phila) 4: 1401–1408.
16. Bon GG, Kenemans P, Dekker JJ, Hompes PG, Verstraeten RA, et al. (1999)
Fluctuations in CA 125 and CA 15–3 serum concentrations during spontaneous
ovulatory cycles. Hum Reprod 14: 566–570.
17. Takano M, Fujii K, Kita T, Kikuchi Y, Uchida K (2004) Amplicon profiling
reveals cytoplasmic overexpression of MUC1 protein as an indicator of
resistance to platinum-based chemotherapy in patients with ovarian cancer.
Oncol Rep 12: 1177–1182.
18. Wreesmann VB, Sieczka EM, Socci ND, Hezel M, Belbin TJ, et al. (2004)
Genome-wide profiling of papillary thyroid cancer identifies MUC1 as an
independent prognostic marker. Cancer Res 64: 3780–3789.
19. Myllykangas S, Junnila S, Kokkola A, Autio R, Scheinin I, et al. (2008)
Integrated gene copy number and expression microarray analysis of gastric
cancer highlights potential target genes. Int J Cancer 123: 817–825.
20. Lacunza E, Baudis M, Colussi AG, Segal-Eiras A, Croce MV, et al. (2010)
MUC1 oncogene amplification correlates with protein overexpression in
invasive breast carcinoma cells. Cancer Genet Cytogenet 201: 102–110.
21. Bieche I, Lidereau R (1997) A gene dosage effect is responsible for high
overexpression of the MUC1 gene observed in human breast tumors. Cancer
Genet Cytogenet 98: 75–80.
22. Waltz MR, Pandelidis SM, Pratt W, Barnes D, Swallow DM, et al. (1998)
A microsatellite within the MUC1 locus at 1q21 is altered in the neoplastic cells
of breast cancer patients. Cancer Genet Cytogenet 100: 63–67.
23. Schroeder JA, Masri AA, Adriance MC, Tessier JC, Kotlarczyk KL, et al. (2004)
MUC1 overexpression results in mammary gland tumorigenesis and prolonged
alveolar differentiation. Oncogene 23: 5739–5747.
24. Feng H, Ghazizadeh M, Konishi H, Araki T (2002) Expression of MUC1 and
MUC2 mucin gene products in human ovarian carcinomas. Jpn J Clin Oncol
32: 525–529.
25. Tashiro Y, Yonezawa S, Kim YS, Sato E (1994) Immunohistochemical study of
mucin carbohydrates and core proteins in human ovarian tumors. Hum Pathol
25: 364–372.
26. Palmer AJ, Lochhead P, Hold GL, Rabkin CS, Chow WH, et al. (2012) Genetic
variation in C20orf54, PLCE1 and MUC1 and the risk of upper gastrointestinal
cancers in Caucasian populations. Eur J Cancer Prev 21: 541–544.
27. Li FX, Yang XX, He XQ, Hu NY, Wu YS, et al. (2012) Association of 10q23
with colorectal cancer in a Chinese population. Mol Biol Rep 39: 9557–9562.
28. Horimasu Y, Hattori N, Ishikawa N, Kawase S, Tanaka S, et al. (2012) Different
MUC1 gene polymorphisms in German and Japanese ethnicities affect serum
KL-6 levels. Respir Med 106: 1756–1764.
29. Ng W, Loh AX, Teixeira AS, Pereira SP, Swallow DM (2008) Genetic
regulation of MUC1 alternative splicing in human tissues. Br J Cancer 99: 978–
985.
30. Marin F, Bonet C, Munoz X, Garcia N, Pardo ML, et al. (2012) Genetic
variation in MUC1, MUC2 and MUC6 genes and evolution of gastric cancer
precursor lesions in a long-term follow-up in a high-risk area in Spain.
Carcinogenesis 33: 1072–1080.
31. Saeki N, Saito A, Choi IJ, Matsuo K, Ohnami S, et al. (2011) A functional single
nucleotide polymorphism in mucin 1, at chromosome 1q22, determines
susceptibility to diffuse-type gastric cancer. Gastroenterology 140: 892–902.
32. Shi Y, Hu Z, Wu C, Dai J, Li H, et al. (2011) A genome-wide association study
identifies new susceptibility loci for non-cardia gastric cancer at 3q13.31 and
5p13.1. Nat Genet 43: 1215–1218.
33. Feng H, Ghazizadeh M, Konishi H, Araki T (2002) Expression of MUC1 and
MUC2 mucin gene products in human ovarian carcinomas. Japanese journal of
clinical oncology 32: 525–529.
34. Tothill RW, Tinker AV, George J, Brown R, Fox SB, et al. (2008) Novel
molecular subtypes of serous and endometrioid ovarian cancer linked to clinical
outcome. Clin Cancer Res 14: 5198–5208.
MUC16 and MUC1 SNPs and Ovarian Cancer Risk
PLOS ONE | www.plosone.org 8 February 2014 | Volume 9 | Issue 2 | e8833435. Pejovic T, Heim S, Mandahl N, Baldetorp B, Elmfors B, et al. (1992)
Chromosome aberrations in 35 primary ovarian carcinomas. Genes Chromo-
somes Cancer 4: 58–68.
36. Thompson FH, Liu Y, Emerson J, Weinstein R, Makar R, et al. (1994) Simple
numeric abnormalities as primary karyotype changes in ovarian carcinoma.
Genes Chromosomes Cancer 10: 262–266.
37. Micci F, Weimer J, Haugom L, Skotheim RI, Grunewald R, et al. (2009)
Reverse painting of microdissected chromosome 19 markers in ovarian
carcinoma identifies a complex rearrangement map. Genes Chromosomes
Cancer 48: 184–193.
38. Sherry ST, Ward MH, Kholodov M, Baker J, Phan L, et al. (2001) dbSNP: the
NCBI database of genetic variation. Nucleic Acids Res 29: 308–311.
39. Bouanene H, Hadj Kacem H, Ben Fatma L, Ben Limem H, Ben Ahmed S, et al.
(2011) Polymorphisms in the MUC16 gene: potential implication in epithelial
ovarian cancer. Pathol Oncol Res 17: 295–299.
40. Carraway KL, Hull SR (1989) O-glycosylation pathway for mucin-type
glycoproteins. Bioessays 10: 117–121.
41. Tabor HK, Risch NJ, Myers RM (2002) Candidate-gene approaches for
studying complex genetic traits: practical considerations. Nat Rev Genet 3: 391–
397.
MUC16 and MUC1 SNPs and Ovarian Cancer Risk
PLOS ONE | www.plosone.org 9 February 2014 | Volume 9 | Issue 2 | e88334